Provenge (sipuleucel-T) is a brand-name injectable drug prescribed for a type of metastatic prostate cancer in adults. The cost of the drug, with and without insurance, can depend on several factors, ...

Much has been said and written about the circumstances surrounding the launch of Dendreon’s innovation in cancer treatment, Provenge, a novel immunotherapeutic treatment for end-stage prostate cancer.

September 29, 2011 — A series of media reports in the past few weeks have detailed mounting problems at Dendreon, the Seattle, Washington–based maker of the immunotherapy sipuleucel-T (Provenge), ...

Provenge (sipuleucel-T) is a brand-name drug that’s prescribed to treat a type of advanced prostate cancer in certain adults. Provenge comes as a liquid that’s typically given as an intravenous (IV) ...

A new survey of cancer doctors published in a research note from investment bank R.W. Baird provides some more reasons for investors to worry about Dendreon and its prostate cancer treatment Provenge, ...

January 6, 2011 — Back in the fall of 2010, the Centers for Medicare and Medicaid Services (CMS) had a problem: their phone lines for an important presscast were at full capacity. As a result, there ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (:EMA) recently provided a positive opinion on Dendreon Corporation’s (DNDN) marketing authorization ...

NEW YORK (Reuters) - In Dendreon Corp's most important clinical trial for the controversial cancer therapy Provenge, researchers analyzed some of the data differently from how the company told U.S.

Prostate cancer treatment zibotentan is looking like less of a threat to Dendreon's (Nasdaq: DNDN) Provenge after AstraZeneca (NYSE: AZN) said that it was stopping a phase 3 trial testing zibotentan ...

Shares of Dendreon surged Thursday after the company said sales of its prostate-cancer therapy Provenge continued to grow in the fourth quarter. Seattle-based Dendreon said sales of Provenge rose to ...

Biotechnology company Dendreon said Wednesday that sales of its prostate cancer drug Provenge continued to climb in the third quarter, although Dendreon took a larger loss as it built up its ...